Communications & Advocacy ∙ Policy & Public Affairs ∙ Sustainability ∙ DE&I ∙ Career Mentor ∙ Lecturer
🙋🏻♂️ The European Hematology Association (EHA) Congress started today. It is interesting to see the number of sessions dedicated to patient centricity. Patient perspective is essential for understanding their experience along the disease journey. #EHA2024 #patientcentricity #patientadvocacy
IMF Chief Medical Officer Dr. Joseph Mikhael takes a deeper dive into the groundbreaking research presented at the American Society of Hematology (ASH) annual meeting, highlighting the AQUILA Clinical Trial's promising findings on high-risk smoldering multiple myeloma. This study demonstrates how early intervention with single-agent daratumumab can delay disease progression and improve survival rates. https://lnkd.in/gkdyYGk9 #ASH24
The American Society of Hematology Annual Meeting is now in full swing in San Diego! Join us at our team's poster presentation, “Health-Related Quality of Life (HRQoL) in Relapsed/Refractory Multiple Myeloma (RRMM): A Systematic Literature Review (SLR) and Meta-Analysis,” today (Monday) from 6-8 PM. In this presentation, we explore baseline (pre-treatment) HRQoL data from published trials and real-world studies using the QLQ-C30 and QLQ-MY20. Specifically, we focus on patients in their second or later line of therapy. This work serves two key purposes: 1. It quantifies the HRQoL burden in patients with multiple myeloma, highlighting important domains and trends across disease and study characteristics. 2. It provides a valuable reference for understanding the impact of established and emerging treatments on patient outcomes. #ASH2024
During #ASH24, Doris Hansen, MD discusses the comparative safety and efficacy of ciltacabtagene autoleucel and idecabtagene vicleucel CAR T-cell therapies in relapsed or refractory multiple myeloma. This study provides valuable information for patient counseling and guides CAR T-cell therapy selection for specific patient populations. ⏰: 12/9 4:00 p.m. PST 📍: San Diego Ballroom AB (Marriott Marquis San Diego Marina) Read more: https://lnkd.in/eGU7ZyJ6 American Society of Hematology #MoffittASH24
#Congress | 🔎 What subjects were amplified by #HCPs through social media during #EHA2024? In June, took place the European Hematology Association (EHA) 2024 Hybrid Congress. The following pages provide a brief overview of the volume of conversations, the share of voice of clinical trials most discussed, or top hashtags. Moreover, discover a focus on #multiplemyeloma with the topics of discussions. Access the SML EHA2024 full report by clicking this link 👉 https://lnkd.in/e6-MYzHj
Learn how clinical lab hematology and hemostasis/thrombosis testing are closely related in interesting clinical cases from ARUP with consideration of both morphologic findings on peripheral blood smears and abnormal hemostasis/thrombosis testing results. https://ow.ly/u1KT50Uwinf
#LegendNews: We are excited to present new findings from our Phase 3 study at this year’s American Society of Hematology (ASH) Annual Meeting & Exposition. This latest data on minimal residual disease (MRD) negativity rates reinforces the strength of our research for those with #MultipleMyeloma. Learn more: https://bit.ly/3BmRJSw #ASH24 #CART
Weekend biotech fun. If in case, you missed promising BEAM-101 clinical data in patients with sickle cell disease (SCD). BEAM-101 is an autologous genetically modified cell therapy. An autologous therapy means that the cells themselves are taken from an individual's own tissues, cells, or DNA. These cells are extracted, edited outside the patient’s body & later restored to help fight SCD.
Today, new safety and efficacy data from the BEACON Phase 1/2 clinical trial of BEAM-101 in patients with sickle cell disease were featured today in the press program for the 66th American Society of Hematology (ASH) Annual Meeting and will be presented in an oral session on Sunday, Dec. 8, 2024, at 10 a.m. PT. Read the full update here: https://lnkd.in/egH4VkmY #DaretoBeam #BeamTeam #ASH24 Beam will host a live and webcast investor event on Dec. 8 at 8:00 p.m. PT to review the key presentations from this year’s ASH meeting. The event will be webcast live and can be accessed under “Events & Presentations” in the Investors section Beam’s website.
Professor of Hematology at Sorbonne University, and head of the Clinical Hematology and Cellular Therapy Department at Saint-Antoine Hospital, Paris, France
Another good news from #ASH24 A landmark analysis of the phase III GMMG-HD7 trial assessing the impact of induction regimen and post-induction and post-transplant MRD on PFS. Post-induction and post-transplantation MRD negativity led to better outcomes in both the Isatuximab-RVd and RVd arms, and Isa-RVd was associated with a PFS benefit vs RVd in MRD+ patients. American Society of Hematology International Myeloma Foundation Controversies in Multiple Myeloma (COMy)
Especially lessons about clinical suspicion and complete blood cell abnormalities should be taught #bloodcancerawereness
Today marks the start of #BloodCancerAwarenessMonth when we shine the spotlight on improving patient care for hematologic malignancies. As the largest Europe-based organization connecting hematologists worldwide, tune in this month to learn about how we work towards Borderless Hematology and where you can go with #EHA: https://eha.fyi/join
During #ASH24, Sadegh Marzban discussed the potential of mechanistic learning in enhancing both the understanding and predictive accuracy of disease progression. Read more: https://lnkd.in/e6ZdNNz6 American Society of Hematology #MoffittASH24
